[HN Gopher] "Pay for success" contracts - a model to develop new...
       ___________________________________________________________________
        
       "Pay for success" contracts - a model to develop new therapies from
       old drugs
        
       Author : savvak
       Score  : 22 points
       Date   : 2021-09-24 10:58 UTC (12 hours ago)
        
 (HTM) web link (crowdfundedcures.medium.com)
 (TXT) w3m dump (crowdfundedcures.medium.com)
        
       | chris_va wrote:
       | I am not sure why this is written as if drug repurposing is an
       | under-explored concept.
       | 
       | Repurposing generics has becoming increasingly popular, because
       | the clinical trial risk is much better in phase 2/3 (where most
       | of the money is lost) than for novel compounds. Combine that with
       | FDA fastrack designation for orphan diseases, and it's become
       | quite the popular space for innovation. Even some of the papers
       | "cited" by this article contradict it.
       | 
       | > This means that if one company pays for the expensive clinical
       | trials showing that a specific treatment protocol for an off-
       | patent drug works in a new indication, they cannot prevent others
       | from "free riding" on this valuable information, which is a "non-
       | rivalrous non-excludable" public good once it is published online
       | 
       | This isn't true. Composition of matter patents are not the only
       | patents. If so, we wouldn't see generic repurposing at all, and
       | obviously that isn't correct.
        
         | pkaye wrote:
         | Colchicine is a very old drug used to treat gout and other
         | diseases which went into orphan disease patent because some
         | company figured out proper dosage. Now the drug became
         | expensive in the US but everywhere else benefited by knowing
         | the proper dosage and no increase in price. I'd rather American
         | consumers not end up solely paying for all these costs.
        
         | 1vuio0pswjnm7 wrote:
         | How do we charge royalties on method of use patents. Do we use
         | prescription data from pharmacies. For the purposes of
         | calculating royalties how do we prove whether and how anyone in
         | posession of a drug actually uses it.
        
       | jawns wrote:
       | My wife and I have been donating to Cures Within Reach
       | https://www.cureswithinreach.org, which funds repurposing
       | research.
       | 
       | This is especially important for rare conditions that are
       | unlikely to ever see robust R&D purely on the basis of the size
       | of the market.
        
       ___________________________________________________________________
       (page generated 2021-09-24 23:00 UTC)